Idebenone Research

Antioxidants for Treatment of Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis.

Ren S, Yao C, Liu Y, Feng G, Dong X, Gao B · Eur Neurol (2022)

Pharmacological treatments for Friedreich ataxia.

Kearney M, Orrell RW, Fahey M, Brassington R, Pandolfo M · Cochrane Database Syst Rev (2016)

Therapeutic interventions for disease progression in Huntington's disease.

Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C · Cochrane Database Syst Rev (2009)

Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.

Garegnani L, Hyland M, Roson Rodriguez P, Escobar Liquitay CM, Franco JV · Cochrane Database Syst Rev (2021)

Leber's Hereditary Optic Neuropathy as a Promising Disease for Gene Therapy Development.

Karaarslan C · Adv Ther (2019)

Effectiveness and safety of treatments for degenerative ataxias: a systematic review.

Trujillo-Martín MM, Serrano-Aguilar P, Monton-Alvarez F, Carrillo-Fumero R · Mov Disord (2009)

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes.

Vogel AP, Folker J, Poole ML · Cochrane Database Syst Rev (2014)

A Review of the Clinical Evidence for Complementary and Alternative Medicine in Huntington's Disease.

Yu M, Bega D · Tremor Other Hyperkinet Mov (N Y) (2019)

Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.

Bourke JP, Bueser T, Quinlivan R · Cochrane Database Syst Rev (2018)

Therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: The LEROS nonrandomized controlled trial

In plain English: The findings of the LEROS study will help guide the clinical management of patients with LHON.

Yu-Wai-Man P, Carelli V, Newman NJ, Silva MJ, Linden A, Van Stavern G, Szaflik JP, Banik R, Lubiński W, Pemp B, Liao YJ, Subramanian PS, Misiuk-Hojło M, Newman S, Castillo L, Kocięcki J, Levin MH, Muñoz-Negrete FJ, Yagan A, Cherninkova S, Katz D, Meunier A, Votruba M, Korwin M, Dziedziak J, Jurkutė N, Harvey JP, La Morgia C, Priglinger C, Llòria X, Tomasso L, Klopstock T, LEROS Study Group. · Cell reports. Medicine (2024)

Pharmacological treatment for aphasia following stroke.

Greener J, Enderby P, Whurr R · Cochrane Database Syst Rev (2001)

Oxidative Stress and Antioxidant Therapies in Friedreich's Ataxia

In plain English: Future studies investigating oxidative stress and antioxidant therapies in FRDA should adopt a prospective, multicenter, long-term, double-blind design.

Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Cárcamo-Fonfría A, Martín-Gómez MA, Agúndez JAG. · Cells (2025)

Idebenone vs. rAAV2-ND4 gene therapy in the treatment of Leber's hereditary optic neuropathy: An indirect comparison meta-analysis

In plain English: Further studies are recommended to formulate a complete idea about the long-term results (>2 years).

Hassan AK, Abu Serhan H. · Indian journal of ophthalmology (2025)

Idebenone does not inhibit disability progression in primary progressive MS.

Kosa P, Wu T, Phillips J, Leinonen M, Masvekar R, Komori M · Mult Scler Relat Disord (2020)

Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia.

Drinkard BE, Keyser RE, Paul SM, Arena R, Plehn JF, Yanovski JA · Arch Phys Med Rehabil (2010)

Effects of idebenone on color vision in patients with leber hereditary optic neuropathy.

Rudolph G, Dimitriadis K, Büchner B, Heck S, Al-Tamami J, Seidensticker F · J Neuroophthalmol (2013)

Persistence of the treatment effect of idebenone in Leber's hereditary optic neuropathy.

Klopstock T, Metz G, Yu-Wai-Man P, Büchner B, Gallenmüller C, Bailie M · Brain (2013)

Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial.

Buyse GM, Goemans N, van den Hauwe M, Thijs D, de Groot IJ, Schara U · Neuromuscul Disord (2011)

Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial.

Buyse GM, Voit T, Schara U, Straathof CSM, D'Angelo MG, Bernert G · Lancet (2015)

Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type.

Bergamasco B, Scarzella L, La Commare P · Funct Neurol (1994)